Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong.
Institute of Digestive Disease, The Chinese University of Hong Kong, Shatin, Hong Kong.
J Gastroenterol Hepatol. 2018 Apr;33(4):934-941. doi: 10.1111/jgh.14003. Epub 2018 Jan 26.
Studies have demonstrated a higher prevalence of diabetes mellitus (DM) in patients with chronic hepatitis C (CHC). Furthermore, coinfection with hepatitis B virus (HBV) is common because of its endemicity in Asian-Pacific regions. The aim of the present study was to investigate the impact of DM and HBV coinfection on the clinical outcomes in Chinese CHC patients.
A territory-wide cohort study was conducted using the database from Hospital Authority, the sole public medical service provider in Hong Kong. CHC patients were identified by the International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis codes, diagnosed between 2000 and 2012. The primary outcome was overall mortality.
A total of 7149 CHC patients were included. Seven hundred twenty-two (10.1%) patients were coinfected with HBV. Their mean age was 56 years; 69.0% were men. The prevalence of DM was similar in mono-infection and coinfection cohorts (22.3% and 21.3%, respectively). Multivariable analysis identified DM as an independent risk factor for death and antiviral treatment for hepatitis C virus (HCV) as an independent protective factor against death. The 5-year survival of CHC patients with mono-infection was better than that of HBV coinfected patients (62.5% vs 57.0%; P = 0.001). The 5-year survival of patients who did or did not receive antiviral treatment for HCV was 94.7% and 55.2%, respectively (P < 0.001).
Hepatitis B virus coinfection and DM were independent risk factors for death in Hong Kong CHC patients. Antiviral treatment for HCV but not HBV was a protective factor against death.
研究表明,慢性丙型肝炎(CHC)患者中糖尿病(DM)的患病率较高。此外,由于乙型肝炎病毒(HBV)在亚太地区流行,HBV 合并感染也很常见。本研究旨在探讨 DM 和 HBV 合并感染对中国 CHC 患者临床结局的影响。
利用香港唯一的公共医疗服务提供者医管局的数据库进行了一项全港范围的队列研究。CHC 患者通过国际疾病分类,第九修订版,临床修正诊断代码确定,诊断时间为 2000 年至 2012 年。主要结局是总体死亡率。
共纳入 7149 例 CHC 患者。722 例(10.1%)患者合并感染 HBV。他们的平均年龄为 56 岁;69.0%为男性。单感染和合并感染队列的 DM 患病率相似(分别为 22.3%和 21.3%)。多变量分析确定 DM 是死亡的独立危险因素,而丙型肝炎病毒(HCV)的抗病毒治疗是死亡的独立保护因素。单感染 CHC 患者的 5 年生存率优于 HBV 合并感染患者(62.5%对 57.0%;P=0.001)。接受或未接受 HCV 抗病毒治疗的患者的 5 年生存率分别为 94.7%和 55.2%(P<0.001)。
HBV 合并感染和 DM 是香港 CHC 患者死亡的独立危险因素。HCV 的抗病毒治疗而不是 HBV 的抗病毒治疗是死亡的保护因素。